HK1034075A1 - 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides - Google Patents

1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides

Info

Publication number
HK1034075A1
HK1034075A1 HK01104490A HK01104490A HK1034075A1 HK 1034075 A1 HK1034075 A1 HK 1034075A1 HK 01104490 A HK01104490 A HK 01104490A HK 01104490 A HK01104490 A HK 01104490A HK 1034075 A1 HK1034075 A1 HK 1034075A1
Authority
HK
Hong Kong
Prior art keywords
hydrohalogenides
isobenzofuran
spiro
fluorophenyl
indole
Prior art date
Application number
HK01104490A
Other languages
English (en)
Inventor
Niels Mork
De Diego Heidi Lopez
Ole Nielsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1034075A1 publication Critical patent/HK1034075A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK01104490A 1997-11-07 2001-06-28 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides HK1034075A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07
PCT/DK1998/000480 WO1999024436A1 (en) 1997-11-07 1998-11-06 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides

Publications (1)

Publication Number Publication Date
HK1034075A1 true HK1034075A1 (en) 2001-10-12

Family

ID=8102935

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01104490A HK1034075A1 (en) 1997-11-07 2001-06-28 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides

Country Status (39)

Country Link
US (2) US6844352B2 (es)
EP (1) EP1044202B1 (es)
JP (1) JP3605358B2 (es)
KR (1) KR100399274B1 (es)
CN (1) CN1105115C (es)
AR (1) AR023010A1 (es)
AT (1) ATE288918T1 (es)
AU (1) AU749094B2 (es)
BG (1) BG64906B1 (es)
BR (1) BR9813949A (es)
CA (1) CA2308745C (es)
CZ (1) CZ288666B6 (es)
DE (1) DE69828999T2 (es)
DZ (1) DZ2642A1 (es)
EA (1) EA002092B1 (es)
EG (1) EG23791A (es)
ES (1) ES2234162T3 (es)
HK (1) HK1034075A1 (es)
HR (1) HRP20000261B1 (es)
HU (1) HUP0100991A3 (es)
ID (1) ID25776A (es)
IL (1) IL135723A (es)
IS (1) IS2342B (es)
JO (1) JO2052B1 (es)
MA (1) MA25585A1 (es)
NO (1) NO325920B1 (es)
NZ (1) NZ504065A (es)
PE (1) PE130299A1 (es)
PL (1) PL190538B1 (es)
PT (1) PT1044202E (es)
RS (1) RS49777B (es)
SK (1) SK285245B6 (es)
TN (1) TNSN98201A1 (es)
TR (1) TR200001267T2 (es)
TW (1) TW483894B (es)
UA (1) UA64769C2 (es)
UY (1) UY25236A1 (es)
WO (1) WO1999024436A1 (es)
ZA (1) ZA9810116B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030453A1 (es) * 2000-08-15 2003-08-20 Lundbeck & Co As H Composicion farmaceutica con contenido de 1' [4-[1-(4-fluorofenil)-1h-indol-3-il]-1-butil] espiro [isobenzofuran-1 (3h), 4'-piperidina]
AU2003263155A1 (en) * 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
WO2004110388A2 (en) * 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
US20090306341A1 (en) * 2005-07-29 2009-12-10 Joachim Emmert LC/MS Blends Containing Ionizing Additives
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
MA25585A1 (fr) 2002-12-31
EG23791A (en) 2007-08-13
KR20010031791A (ko) 2001-04-16
NO325920B1 (no) 2008-08-18
EP1044202A1 (en) 2000-10-18
PT1044202E (pt) 2005-04-29
HRP20000261A2 (en) 2001-04-30
DZ2642A1 (fr) 2004-12-28
ATE288918T1 (de) 2005-02-15
DE69828999T2 (de) 2005-07-21
US20030055074A1 (en) 2003-03-20
EP1044202B1 (en) 2005-02-09
ZA9810116B (en) 1999-05-07
BG64906B1 (bg) 2006-08-31
NO20002188L (no) 2000-06-14
PE130299A1 (es) 1999-12-16
BR9813949A (pt) 2000-09-26
CN1278823A (zh) 2001-01-03
US20050171135A1 (en) 2005-08-04
CA2308745C (en) 2004-01-20
CN1105115C (zh) 2003-04-09
DE69828999D1 (de) 2005-03-17
JO2052B1 (en) 1999-05-15
CA2308745A1 (en) 1999-05-20
PL190538B1 (pl) 2005-12-30
SK285245B6 (sk) 2006-09-07
BG104485A (en) 2001-01-31
HUP0100991A3 (en) 2003-03-28
TW483894B (en) 2002-04-21
IS5460A (is) 2000-04-18
TR200001267T2 (tr) 2000-09-21
EA200000502A1 (ru) 2000-10-30
IL135723A0 (en) 2001-05-20
NO20002188D0 (no) 2000-04-27
AR023010A1 (es) 2002-09-04
SK6462000A3 (en) 2000-10-09
JP2001522852A (ja) 2001-11-20
WO1999024436A1 (en) 1999-05-20
US6844352B2 (en) 2005-01-18
YU23500A (sh) 2003-12-31
HUP0100991A2 (hu) 2001-09-28
CZ288666B6 (cs) 2001-08-15
KR100399274B1 (ko) 2003-09-26
RS49777B (sr) 2008-06-05
NZ504065A (en) 2002-05-31
UA64769C2 (uk) 2004-03-15
ES2234162T3 (es) 2005-06-16
ID25776A (id) 2000-11-02
AU1022699A (en) 1999-05-31
TNSN98201A1 (fr) 2005-03-15
JP3605358B2 (ja) 2004-12-22
CZ20001663A3 (cs) 2000-10-11
UY25236A1 (es) 2000-12-29
AU749094B2 (en) 2002-06-20
PL340220A1 (en) 2001-01-15
IL135723A (en) 2005-11-20
HRP20000261B1 (en) 2009-04-30
IS2342B (is) 2008-02-15
EA002092B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
HK1034075A1 (en) 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides
GB2308553B (en) Microporous ink-jet recording elements
IL113472A0 (en) Non-peptidyl tachykinin receptor antogonists
AU1474495A (en) Fence adjustment mechanism
ZA983344B (en) Superabsorbers having controlled absorption rate
AU3558389A (en) Printer control device
GB2314599B (en) Post height adjustment for dental equipment
AU1578799A (en) Anchoring mechanism for a guide post
EP0861563A4 (en) MECHANISM FOR CELL ASSIGNMENT
SI1044202T1 (en) 1'- 4- 1- (4-fluorophenyl)- 1h-indole-3-yl) -1-butyl)-spiro isobenzofuran- 1(3h),4'- piperidine) hydrohalogenides
HUP0101706A3 (en) Use of 1'-[4-[1-(4-fluorphenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzo-furan-1(3h),4'-piperidine] for the preparation of pharmaceutical composition treating panic attacks
NZ329359A (en) Spiro[2h 1 benzopyran -2,4'-piperidine] derivatives and medicaments thereof
DK1044202T3 (da) 1'-[4-[1-(4-Fluorphenyl)-1H-indol-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4'-piperidin]hydrohalogenider
AU2001279607A1 (en) Pharmaceutical composition containing 1'-(4-(1-(4-fluorophenyl)-1h-indole-3-yl) -1-butyl)-spiro(isobenzofuran-1(3h),4'-piperidine)
AU717385C (en) Guide post
AU3403593A (en) Improved height adjustment device
AUPO499397A0 (en) Guide post
HU9503664D0 (en) Spiro(quinazolyl-piperidine)derivatives
PL311768A1 (en) Square set anchoring mechanism
AU5290690A (en) Adjustment arrangement for tilt-slab construction
SG71688A1 (en) Alcatel alsthom
GB9508985D0 (en) Adjustment mechanism
AU125794S (en) Adjustment mechanism
TW307246U (en) Discharging mechanism with fine adjustment
SI0853619T1 (en) Disubstituted piperidine derivatives

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091106